source
- J&J and Contineum's oral M1 inhibitor fails second mid-stage depression trialContineum Therapeutics and Johnson & Johnson reported that their oral M1 receptor inhibitor, known as PIPE-307 or JNJ-5120, did not meet its primary endpoints in a Phase II study for major depressi…
- Blood centers poised to boost cell and gene therapy supply chainsBlood centers have the donors, resources and community footprint that drug sponsors need to address supply chain bottlenecks for cell and gene therapies. Cell and gene therapies such as CAR‑T and…